DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives ...

DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line ...

DexCom, Inc. DXCM is well-positioned for growth in the coming quarters, supported by the significant potential of the ...

Signos raised $20 million to expand its glucose monitoring platform for weight loss, which pairs Dexcom’s over-the-counter ...

CGMs can help people avoid serious diabetes complications, save money through better management and adjust behavior based on ...

In May 2026, Dexcom disclosed FDA-enforced, Class II voluntary recalls of its G7 and ONE/ONE+ iOS and watchOS apps worldwide due to a software defect that can delay or replay glucose readings and ...

First off, it announced today that it plans to acquire Nutrisense — a CGM startup that targets nondiabetics. Stelo, its over-the-counter CGM, is also getting an FDA-cleared redesign that includes ...

Discordance between continuous glucose monitoring measures and A1c should not always be interpreted as measurement errors, ...

The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...

The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling. Dexcom said it traced sales of the ...

SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...

Medicaid coverage is state-dependent. Some states provide CGMs with no cost-sharing, while others limit eligibility to Type 1 ...